![]() |
|
|
Vol. 29, Issue 7, 976-982, July 2001
University of Utrecht, Research Group for Comparative
Endocrinology, Graduate School for Developmental Biology, Utrecht, The
Netherlands (M.J.B., M.G.W., F.v.W., J.G.D.L., H.J.Th.G.); and Organon
NV, Oss, The Netherlands (A.G.H.E., H.J.K., C.H.J.V.)
The 19-nor-progestogen norethisterone is used as a progestogen
component in contraceptives and in continuous- and sequential combined
hormone replacement therapy (HRT) in postmenopausal women. Metabolism of norethisterone in HRT target tissues may play a role in
its biological response. The aim of this study was to investigate which
steroid-metabolizing enzymes are present in rat uterus, vagina, and
aorta, three HRT target tissues. Next, the ability of the tissues to
metabolize norethisterone was assessed. Furthermore, to investigate the
effect of substituents at the 7- and 11-position, the metabolism of Org
OM38 (7
-methyl-norethisterone), Org 4060 (11
-ethyl-norethisterone), and Org 34694 (7
-methyl,11-ethylidene-norethisterone) was studied. Using
radiolabeled progesterone, the presence of 20
-hydroxysteroid
dehydrogenase, 5
-reductase, and 3
-hydroxysteroid dehydrogenase
activity could be demonstrated in uterus, vagina, and to a lesser
extent in aorta. The combined action of the latter two enzyme
activities resulted in 3
-OH,5
-H-norethisterone as the major
metabolite of radiolabeled norethisterone in uterus (26.9%), vagina
(37.1%), and aorta (1.4%). The norethisterone derivatives, however,
were metabolized to a much lesser extent (1.0-7.6%). No formation of
5
-reduced forms of Org 4060, Org OM38, or Org 34694 was found, while
formation of minor amounts of 3
-OH-Org 4060 and 3
-OH-Org OM38
could be demonstrated in both uterus, vagina, and aorta. These findings
confirm the role of 5
-reductase as a rate-limiting step in the
metabolism of norethisterone derivatives and show important inhibitory
effects of substituents at the 7
- and 11-position of the steroid
skeleton on 5
-reduction.